GlassScriptPhysician profile
Mark D Frazee
NPI 1295999001
$747.93
in general payments reported to CMS, 2019-2025
15 companies · $337 in 2025
The $337 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $11.26 · 2022: $21.77 · 2023: $178 · 2024: $200 · 2025: $337.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $714.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $160.29 | 2023-2025 | Breztri, Airsupra |
| Actelion Pharmaceuticals US, INC. | $152.72 | 2024-2025 | Opsumit, Uptravi, Opsynvi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $123.79 | 2025 | Xifaxan |
| Genzyme Corporation | $53.78 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $33.65 | 2024-2025 | Glassia |
| Mylan Specialty L.P. | $30.22 | 2023-2024 | Yupelri |
| Verona Pharma, INC. | $30.21 | 2025 | Ohtuvayre |
| Pfizer INC. | $26.45 | 2021-2025 | |
| Viatris Specialty LLC | $25.74 | 2025 | Yupelri |
| Janssen Pharmaceuticals, INC | $21.77 | 2022 | |
| Insmed, INC. | $20.02 | 2024 | Arikayce |
| Bayer Healthcare Pharmaceuticals INC. | $19.30 | 2025 | |
| Grifols USA, LLC | $17.85 | 2023 | Prolastin-C Liquid |
| Electromed, INC. | $17.67 | 2025 | Smartvest |
| Glaxosmithkline, LLC. | $14.47 | 2025 | Nucala |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Frazee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.